Almost every drug approved over the past two decades has changed stewardship during the course of its development.

Curadev works in the early stages of the drug discovery and development phase and has always welcomed interest from organizations with strengths and expertise that can bring out the value of our portfolio. We have been successful in establishing alliances with some of the world’s most innovative biotechs and prestigious pharmaceutical firms.

April 2020

Curadev and Karyopharm, USA sign a drug discovery collaboration agreement under which Curadev will select a target for co-development until Phase 1 clinical trials before handing the drug candidate over to Karyopharm for further development.

Read more...

March 2020

Curadev and Bayer, Germany, sign a research collaboration and license agreement to develop novel STING antagonists

Read more...

September 2019

Curadev receives first milestone payment from the out-licensing of its novel small molecule STING agonists to Takeda Pharmaceuticals

May 2019

Curadev announces licensing of its patents covering its novel small molecule STING agonists to Takeda Pharmaceuticals

Read more...

April 2015

Curadev announces research collaboration and licensing agreement to develop cancer immunotherapeutic with Roche  

Read more...

May 2013

Curadev partners its dual kinase inhibitor program with Medivation, Inc, USA

September 2012

Curadev receives first milestone payment in its immune oncology small molecule collaboration with Endo Pharma

October 2011

Curadev signs extensive research collaboration deal with Medivation, Inc, USA

April 2011

Curadev announces research collaboration and licensing agreement to develop cancer immunotherapeutic deal with Endo Pharma